"The platform, while focused initially on cancer, could theoretically be applied to a range of other conditions"

The immuno-oncology antibody developer added $7m to a round already containing University of Texas system's MD Anderson, which helped spin out OncoResponse a year ago.

The advanced electrocardiogram developer, spun out of Stanford University, has set the range for an initial public offering sized at up to $91m.

The immuno-oncology antibody developer added $7m from Helsinn and GreatPoint to a round already containing Baxalta, MD Anderson and Alexandria Real Estate Equities.

Cancer care group Helsinn has put $50m into a corporate venturing unit called Helsinn Investment Fund that will target early-stage companies.

The advanced electrocardiogram developer has set the range for an initial public offering sized at up to $91m, with Novo, Kaiser Permanente and St. Jude set to exit.

SoftBank led the microbe engineering technology company's latest round, bringing its overall funding to $174m in less than 18 months.

Crispr Therapeutics, a gene editing drug developer backed by Bayer, Vertex, Celgene and GlaxoSmithKline, has set the terms for an offering on Nasdaq.

Eccrine Systems is developing advanced, wearable, sweat sensing systems based on research and intellectual property that originated from Cincinnati University and the Air Force Research Labs at Wright Patterson Air Force Base.